This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst

7/30/15 12:37 PM EDT
Fate Therapeutics (FATE) is developing several small molecules which modulate umbilical cord stem cells. Reni Benjamin, Senior Biotechnology Analyst at Raymond James Financial, said the company’s shares, already up over 40% this year, could head higher in the second half. 'Umbilical cords are being used more and more in bone marrow transplants, but there are a lot of problems with umbilical cords including trying to expand these cells and get them to work really well,' said Benjamin. 'Fate has developed a drug that can now make these cells do better in the human body.' Elsewhere in the regenerative medicine arena, Benjamin is bullish on Ocata Therapeutics (OCAT), down 32% year-to-date, which is in the ophthalmology space, as well as Pluristem (PSTI), a $185 million Israel-based biotherapeutics company. Shares of Pluristem have fallen 5% so far in 2015, but Benjamin expects a second half turnaround. Another stock Benjamin is positive on is Capricor (CAPR), which develops cardiovascular drugs and sports a $70 million market-cap. The company’s shares have been on a wild ride in 2015, surging from $4 a share in January to more than $10 in March on news that it was moving into the Duchenne Muscular Dystrophy space before eventually falling back to where it started.
Stocks in this video: FATEPSTICAPROCAT
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs